Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (tisotumab vedotin-tftv). Access to the event can be obtained as follows: September 21, 2021 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278 Webcast with slides will be available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company’s website. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference(…) Read More »